A Study to Learn How the Study Medicine Called PF-08653944 is Taken up Into the Blood in Adults With Overweight or Obesity

NCT07400679 | Active Not Recruiting Phase 1 FDA Drug

• 1 other identifier: C6491016
• Study Type: interventional
• Target: 54
• Locations: 1 country
• Sites: 1

Brief Summary

This study is being done to learn how the study medicine affects the body and how safe it is for people who take it. The researchers will look at a number of health tests, including blood tests such as calcitonin, amylase, and lipase, because similar medicines have sometimes caused changes in these tests. This study is seeking participants who are:

• Adults who are obese or overweight with weight-related health conditions, and
• Meet health and other checks assessed by the study doctor. The study team will give a single dose of the study treatment at the clinic to the participants. At each study visit, blood samples will be collected, vital signs will be checked, and the study team will ask about any reactions or health changes. Vital signs are basic measurements that show how well the body is working. They help the study team quickly understand a participant's overall health. These usually include body temperature, heart rate, breathing rate, and blood pressure. The study involves multiple clinic visits at a study site over the length of the study. The information collected will help researchers understand how the study medicine works and whether it is safe.

Conditions

Overweight; Obesity; Healthy

Keywords

Obesity; Overweight

Outcome Measures

Primary Outcomes (2)

• Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of PF-08653944

  To assess the relative bioavailability of SC to the thigh or upper arm compared to the abdomen

  Up to 85 days

• PK: Maximum Observed Concentration (Cmax) of PF-08653944

  To assess the relative bioavailability of SC to the thigh or upper arm compared to the abdomen

  Up to 85 days

Secondary Outcomes (1)

• Number of Participants With Treatment Emergent Adverse Events (TEAEs)

  Up to 85 Days

Study Arms (4)

Treatment 1

EXPERIMENTAL

Participants will receive a single subcutaneous (SC) dose of PF-08653944 on Day 1 administered to the abdomen.

Drug: PF-08653944

Treatment 2

EXPERIMENTAL

Participants will receive a single SC dose of PF-08653944 on Day 1 administered to the thigh.

Drug: PF-08653944

Treatment 3

EXPERIMENTAL

Participants will receive a single SC dose of PF-08653944 on Day 1 administered to the upper arm.

Drug: PF-08653944

Treatment 4 (Optional)

EXPERIMENTAL

Japanese participants will receive a single SC dose of PF-08653944 on Day 1 administered to the abdomen.

Drug: PF-08653944

Interventions

PF-08653944 DRUG

Solution for injection

Also known as: MET097

Treatment 1; Treatment 2; Treatment 3; Treatment 4 (Optional)

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Participants 18 years of age or older at Screening who are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, and ECGs.
• BMI of 27-45 kg/m2 ; and a total body weight \>50 kg (110 lb).
• For Japanese participants only: BMI of 20-45 kg/m2 and a total body weight \>50 kg (110 lb) and must have 4 biological Japanese grandparents who were born in Japan.

You may not qualify if:

• Pregnant or breastfeeding women, or those planning pregnancy during the study.
• Clinically significant medical conditions including hematologic, renal, endocrine, pulmonary, gastrointestinal (including pancreatitis, gallbladder disease, clinically relevant gastric emptying disorders), cardiovascular, hepatic, psychiatric, neurologic, or severe allergic diseases.
• Personal or first-degree family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN2), or suspected MTC.
• Active or recent suicidal ideation in the past year, suicidal behavior within the past 5 years, or any psychiatric condition that increases risk in the investigator's judgment.
• Clinically significant gastric emptying abnormality or chronically taking drugs that directly affect GI motility.
• Acute gastrointestinal symptoms at screening or Day -1.
• Known hypersensitivity to PF-08653944, GLP-1 receptor agonists, or any excipients.
• Prior participation in any study involving PF-08653944 (formerly MET097) with at least one dose received.

Sponsors & Collaborators

• Pfizer: lead

Study Sites (1)

New Haven Clinical Research Unit

New Haven, Connecticut, 06511, United States

Location

Related Links

• To obtain contact information for a study center near you, click here.

MeSH Terms

Conditions

Overweight; Obesity

Condition Hierarchy (Ancestors)

Overnutrition; Nutrition Disorders; Nutritional and Metabolic Diseases; Body Weight; Signs and Symptoms; Pathological Conditions, Signs and Symptoms

Study Officials

• Pfizer CT.gov Call Center

  Pfizer

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: BASIC SCIENCE
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: February 3, 2026
• First Posted: February 10, 2026
• Study Start: February 4, 2026
• Primary Completion (Estimated): September 18, 2026
• Study Completion (Estimated): September 18, 2026
• Last Updated: May 18, 2026

Record last verified: 2026-05

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)